Suppression of acute bone marrow edema (osteitis) in the sacroiliac joints with long-term use of non-steroidal anti-inflammatory drugs in patients with axial spondyloarthritis
https://doi.org/10.14412/1996-7012-2023-2-82-85
Abstract
Long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) is a concern for both doctors and patients. However, in axial spondyloarthritis (axSpA), NSAIDs are used not only as a symptomatic therapy, but also to prevent the progression of the disease. Therefore, in active axSpA, NSAIDs are recommended to be administered for a much longer period of time than it is indicated in the instructions for use of the drug. The article presents two clinical cases of long-term use of etoricoxib in active axSpA. In both cases, clinical efficacy and resolution of active osteitis in the sacroiliac joints, good tolerability of treatment were noted.
Keywords
axial spondyloarthritis,
active sacroiliitis,
osteitis,
non-steroidal anti-inflammatory drugs,
etoricoxib
Supporting agencies: The article was prepared within the framework of the fundamental scientific topic "Pathogenetic features and personalized therapy of ankylosing spondylitis and psoriatic arthritis" №АААА-А19-119021190147-6
About the Authors
Sh. F. Erdes
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Shandor Fedorovich Erdes
34A, Kashirskoe Shosse, Moscow 115522
A. S. Starkova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
References
1. Erdes ShF, Rebrov AP, Dubinina TV, et al. Spondyloarthritis: modern terminology and definitions. Terapevticheskii arkhiv. 2019; 91(5):84-8. (In Russ.).
2. Gaidukova IZ, Rebrov AP, Lapshina SA, et al. Use of nonsteroidal anti-inflammatory drugs and biological agents for the treatment of axial spondyloarthritides. Recommendations of the Spondyloarthritis Study Group of Experts, All-Russian Public Organization «The Association of Rheumatology of Russia». Nauchno-Prakticheskaya Revmatologiya. 2017;55(5):474-84. (In Russ.).
3. Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care Res (Hoboken). 2019 Oct;71(10): 1285-99. doi: 10.1002/acr.24025. Epub 2019 Aug 21.
4. Van der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017 Jun;76(6): 978-91. doi: 10.1136/annrheumdis-2016210770. Epub 2017 Jan 13.
5. Rumyantseva DG, Dubinina TV, Erdes ShF. Impact of the frequency of using nonsteroidal anti-inflammatory drugs on the radiographic progression of sacroiliitis in patients with early axial spondyloarthritis. Nauchno-Prakticheskaya Revmatologiya. 2018;56(3):346-50. (In Russ.).
6. Gaydukova IZ, Rebrov AP, Nam IF, Kirsanova NV. Etoricoxib in the treatment of active sacroiliitis in patients with axial spondyloarthritis, including ankylosing spondylitis. Terapevticheskii Arkhiv. 2014;86(12):42-47. (In Russ.).
7. Van der Heijde D, Dijkmans B, Geusens P, et al. Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005 Feb; 52(2):582-91. doi: 10.1002/art.20852.
8. Van der Heijde D, Kivitz A, Schiff MH, et al; ATLAS Study Group. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006 Jul;54(7):2136-46. doi: 10.1002/art.21913.
9. Inman RD, Davis JC Jr, van der Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008 Nov;58(11):3402-12. doi: 10.1002/art.23969.
10. Sieper J, Lenaerts J, Wollenhaupt J, et al. Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis. Results from a 6-month, randomised, open-label follow-up study, INFAST Part 2. Ann Rheum Dis. 2014 Jan;73(1):108-13. doi: 10.1136/annrheumdis2013-203460. Epub 2013 Jun 5.
11. Poddubnyy D, Listing J, Sieper J. Brief Report: Course of Active Inflammatory and Fatty Lesions in Patients With Early Axial Spondyloarthritis Treated With Infliximab Plus Naproxen as Compared to Naproxen Alone: Results From the Infliximab As First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial. Arthritis Rheumatol. 2016 Aug;68(8):1899-903. doi: 10.1002/art.39690.
12. Karateev AE, Nasonov EL, Ivashkin VT, et al. Rational use of nonsteroidal anti-inflammatory drugs. Clinical guidelines. Nauchno-Prakticheskaya Revmatologiya. 2018;56(Suppl. 1):1-29. (In Russ.).
Review
For citations:
Erdes SF, Starkova AS. Suppression of acute bone marrow edema (osteitis) in the sacroiliac joints with long-term use of non-steroidal anti-inflammatory drugs in patients with axial spondyloarthritis. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2023;17(2):82-85. (In Russ.) https://doi.org/10.14412/1996-7012-2023-2-82-85
Views:
1243
Email this article 